![](https://porib.com/wp-content/uploads/2021/07/Lung-Cancer.jpg)
Isla D, Massuti B, Lázaro M, Ruiz de Alda L, Gordo R, Ortega-Joaquín N, Oyagüez I
Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
Lung Cancer Management 2020. doi.org/10.2217/lmt-2019-0011
![](https://porib.com/wp-content/uploads/2021/07/Pharmaco-Open.jpg)
de Andrés-Nogales F, Casado MÁ, Trillo JL, Ruiz-Moreno JM, Martínez-Sesmero JM, Peralta G, Poveda JL, Ortiz P, Ignacio E, Zarranz-Ventura J, Udaondo P, Mur C, Álvarez E, Cervera E, Martínez M, Llorente I, Zulueta J, Rodríguez-Maqueda M, García-Layana A, Martínez-Olmos J